Shareholders are very likely to turn down the Michael Saylor pitch, Polymarket bettors are predicting. …
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) …